Vaxart, Inc. Files 8-K on Executive Changes and Disclosures

TL;DR

Vaxart filed an 8-K detailing exec changes and disclosures. Stay tuned.

AI Summary

Vaxart, Inc. filed an 8-K on September 2, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. The filing also includes Regulation FD disclosures and financial statements and exhibits.

Why It Matters

This filing provides updates on Vaxart's corporate governance and executive appointments, which can impact investor confidence and strategic direction.

Risk Assessment

Risk Level: medium — Changes in directors or officers, especially if unexpected, can signal internal shifts or strategic realignments that may affect the company's future performance.

Key Players & Entities

• Vaxart, Inc. (company) — Registrant
• September 2, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 001-35285 (company_id) — Commission File Number
• 59-1212264 (company_id) — EIN

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock , $0.0001 par value VXRT The Nasdaq Capital M

Filing Documents

• vxrt20250902_8k.htm (8-K) — 28KB
• ex_858784.htm (EX-99.1) — 9KB
• 0001437749-25-028167.txt ( ) — 169KB
• vxrt-20250902.xsd (EX-101.SCH) — 3KB
• vxrt-20250902_def.xml (EX-101.DEF) — 11KB
• vxrt-20250902_lab.xml (EX-101.LAB) — 15KB
• vxrt-20250902_pre.xml (EX-101.PRE) — 11KB
• vxrt20250902_8k_htm.xml (XML) — 3KB

02

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 2, 2025, Michael J. Finney, Ph.D. provided notice of his retirement from the board of directors (the "Board") of Vaxart, Inc. (the "Company"), including as Chair of the Board and as Chair and a member of the Science and Technology Committee, effective September 30, 2025. Dr. Finney's retirement was for personal reasons and was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices. In connection with Dr. Finney's retirement from the Board, the Board reduced the size of the Board from six to five members, effective upon the retirement of Dr. Finney.

01

Item 7.01 Regulation FD Disclosure. On September 2, 2025, the Company issued a press release regarding Dr. Finney's retirement from the Board. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 and Exhibit 99.1 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01 and in the accompanying Exhibit 99.1 shall not be deemed incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof regardless of any general incorporation language in such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. Exhibit No. Description 99.1 Press Release, dated September 2, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 2, 2025 VAXART, INC. By: /s/ Steven Lo Steven Lo President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR